News
Latest News
". . . if the branded manufacturer denies the provision of samples, it can delay its competitor’s approval and prop up its own drug’s high costs. This should not be happening. . . . The CREATES Act will prevent this kind of gaming and make sure that generic and biosimilar manufacturers can gain samples to complete testing and win FDA approvals."
"The Preserve Access to Affordable Generics and Biosimilars Act would . . . accelerate the lowering of prescription drug prices in America. . . . [and] prevent anticompetitive settlements that line drug company pockets while consumers pay the bill."
“The Prescription Pricing for the People Act of 2019 would shed light on how PBMs are affecting prescription costs and patient choice. This would support Congress as it crafts evidence-based solutions to address the anticompetitive role PBMs play as pharmaceutical costs continue to rise.”
"A review of some of the passages from pages 168-180 make the summary on page 7-8 crystal clear in recognizing the summary is about congressional lawmaking authority under separation-of-powers when constitutional tensions exist between the President’s official Article II actions and obstruction of justice statutes. . .
" . . . today's subpoena is wildly overbroad. It commands the department to provide Congress with millions of records that would be plainly against the law to share . . . The chairman's process flies in the face of normal and proper congressional oversight."
"In the coming weeks and months, I expect to see continued, robust activity from the Department to fully implement the First Step Act. I stand ready to partner with you in ensuring the First Step Act is fully and effectively implemented."